Siemens Healthineers (ETR:SHL) has been given a €55.30 ($65.06) target price by stock analysts at JPMorgan Chase & Co. in a research note issued on Monday, Borsen Zeitung reports. The firm currently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 14.23% from the company’s previous close.
SHL has been the topic of a number of other reports. Sanford C. Bernstein set a €53.00 ($62.35) target price on Siemens Healthineers and gave the stock a “buy” rating in a research report on Wednesday, February 3rd. UBS Group set a €46.00 ($54.12) price target on shares of Siemens Healthineers and gave the stock a “neutral” rating in a research note on Tuesday, February 23rd. Deutsche Bank Aktiengesellschaft set a €46.00 ($54.12) price target on shares of Siemens Healthineers and gave the stock a “neutral” rating in a research note on Monday, February 8th. Independent Research set a €48.00 ($56.47) price target on shares of Siemens Healthineers and gave the stock a “neutral” rating in a research note on Friday, March 26th. Finally, Berenberg Bank set a €56.00 ($65.88) price target on shares of Siemens Healthineers and gave the stock a “buy” rating in a research note on Thursday, April 29th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of €49.52 ($58.25).
SHL stock opened at €48.41 ($56.95) on Monday. Siemens Healthineers has a twelve month low of €35.58 ($41.85) and a twelve month high of €49.99 ($58.81). The company has a market cap of $54.56 billion and a PE ratio of 32.24. The business’s 50-day simple moving average is €47.06 and its 200 day simple moving average is €43.59. The company has a quick ratio of 1.02, a current ratio of 1.36 and a debt-to-equity ratio of 45.68.
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems.
Recommended Story: Trade Deficit
Receive News & Ratings for Siemens Healthineers Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siemens Healthineers and related companies with MarketBeat.com's FREE daily email newsletter.